Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN6047 hydrochloride crossover trial in peripheral neuropathic pain with mechanical allodynia
2024-517304-12-00Phase 2Authorised
- Sponsor
- PharmNovo
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of PN6047 in Peripheral neuropathic pain (2 arms), sponsored by PharmNovo. Primary endpoints: Safety parameters and Adverse events. Planned start Sep 2025; status: authorised.
02
Drugs
PN6047
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on 2024-517304-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517304-12-00.